<DOC>
	<DOCNO>NCT01784393</DOCNO>
	<brief_summary>Pain bone metastasis breast cancer origin treat localized radiation . Modulating dos schedule show little efficacy improve result . Given synergistic therapeutic effect report combined systemic chemotherapy local radiation anal , rectal , head neck malignancy , investigator seek evaluate tolerability efficacy combine capecitabine radiation palliation pain due bone metastasis breast cancer Hypothesis : Given hypothesis regimens employ great intensity radiation yield high rate pain relief , radiosensitization use tumor target drug like Xeloda improve rate complete pain relief compare radiosensitization 5FU alone . Primary Objective : To determine frequency duration pain relief narcotic relief propose regimen . Secondary Objective : To determine toxicity concurrent Capecitabine radiotherapy breast cancer patient bone metastasis .</brief_summary>
	<brief_title>Chemoradiation Bone Metastasis</brief_title>
	<detailed_description>BACKGROUND Much clinical practice oncology involve palliative care . In set , emphasis alleviation symptom preservation improvement quality life . A large body clinical evidence document effectiveness local-field external beam radiotherapy palliation pain osseous metastasis ( 1 ) . Despite general agreement , controversy remain regard optimal dose fractionation schedule . Prospective phase III clinical trial ( 2-6 ) , today , fail demonstrate superiority one schedule another , result , pattern practice remain diverse duration intensity . Between 1974 1980 RTOG conduct large national study determine effectiveness five different dose fractionation schedule ( 2 ) . A total 1016 patient enter ,266 `` solitary metastasis '' stratum , 750 `` multiple metastasis `` stratum . The former randomly assign treatment 40,5Gy 15 fraction 20Gy 5 fraction . The latter assign 30Gy 10 fraction , 15 Gy in5 fraction ,20 Gy 5 fraction , 25 Gy 5 fraction . A quantitative measure pain , base severity frequency pain , type frequency pain medication use , devised evaluate response . Overall , 89 % patient experience minimal relief . There significant difference treatment arm stratum . The initial pain score find useful predictor ; patient high score less likely respond less likely experience complete response . Patients breast prostate cancer significantly likely respond patient lung primary lesion . Patients complete treatment plan significantly high rate complete response .While relief experience almost invariably within first four week , complete relief first report later four week start treatment 50 % patient .The median duration minimal complete pain relief 20 12 week , respectively . There significant difference duration pain relief different arm It conclude treatment dose schedule equally effective . A reanalysis RTOG study report Blitzer ( 7 ) .Using stepwise logistic regression , examine effect number fraction , dose per fraction , solitary versus multiple metastasis , probability attain complete pain relief need retreatment . This multivariate technique allow patient solitary multiple metastasis analyze together . By increase number subject event statistical power analysis outcome . There correlation time dose factor outcome ( 8 ) . It conclude protracted schedule result improved pain relief . Price et al . randomize 288 patient receive either 8 Gy one fraction 30 Gy 10 daily fraction . Pain assess use questionnaire complete patient home daily basis . No difference find probability attain pain relief , speed onset duration relief two arm ( 4 ) . Hoskin et al . randomize 270 patient receive either 4 Gy 8 Gy one fraction ( 3 ) Pain assessed patient ) analgesic usage record treatment 2,4,8 12 week . At 4 week response rate 69 % 8 Gy 44 % 4 Gy ( p &lt; 0.001 ) . The duration effect independent dose . Two randomized trial report ( 5,6 ) . Given small difference Biological Effective Dose ( BED ) arm ( 6 ) small number patient accrue ( 5,6 ) , surprising difference treatment arm detect . RTOG report result pool data dose response analysis ( 11 ) . A computerized literature search conduct identify prospectively randomized clinical study address issue result study ( 2 6 ) pool together form database analysis . The endpoint select analysis complete response ( CR ) . It felt endpoint likely evaluate consistent fashion different investigator . One study ( 6 ) exclude analysis outcome report use conventional definition complete partial response . To allow comparison different study arm , BED calculate schedule . Odds ratio calculate various dose level show statistically significant increase 1.00 3.32 BED increase 14.4 Gy 5 1.4 Gy . For first time , RTOG analysis demonstrate highly significant dose response relationship palliation pain bone metastases radiotherapy . Furthermore , evidence flatten dose¬-response curve within dose range test , suggest gain realize dos outside range test . We propose phase II clinical trial biological effective dose increase concurrent use radiosensitizer . The main advantage approach escalation physical dose avoidance increase overall treatment time . Capecitabine fluoropyrimidine carbamate antineoplastic activity . It orally administer systemic prodrug 5 ' deoxy 5 fluorouridine ( 5 ' DFUR ) convert 5 Capecitabine readily absorb gastrointestinal tract . In liver , 60 kDa carboxyesterase hydrolyze much compound 5 ' deoxy 5 fluorocytidine ( 5 ' DFCR ) . Cytidine deaminase , enzyme find tissue , include tumor , subsequently convert 5 ' DFCR 5 ' deoxy 5 fluorouridine ( 5 ' DFUR ) .. The enzyme , thymidine phosphorylase ( dThdPase ) , hydrolyze 5 ' DFUR active drug 5 FU . Many tissue throughout body express thymidine phosphorylase . Some human carcinoma express enzyme high concentration surround normal tissue . Both normal tumor cell metabolize 5 FU 5¬fluoro 2 deoxyuridine monophosphate ( FdUMP ) 5 fluorouridine triphosphate ( FUTP ) . These metabolite cause cell injury two different mechanism . First , HUMP folate cofactor , N5 10¬methylenetetrahydrofolate , bind thymidylate synthase ( TS ) form covalently bound ternary complex . This bind inhibits formation thymidylate uracil . Thymidylate necessary precursor thymidine triphosphate , essential synthesis DNA , deficiency compound inhibit cell division . Second , nuclear transcriptional enzyme mistakenly incorporate FUTP place uridine triphosphate ( UTP ) synthesis RNA . This metabolic error interfere RNA process protein synthesis . Capecitabine already approve use patient metastatic breast cancer resistant paclitaxel anthracycline contain chemotherapy regimen . Although 5FU establish radiosensitizer , exact mechanism enhances cell kill well understood . Sensitization schedule dependent maximal cytocidal concentration 5FU give radiation exposure ( 12 ) . The effect result increase sublethal damage inhibition sublethal damage repair ( 12,13 ) . Current evidence suggest radiosensitization 5FU mediated effect DNA rather RNA ( 14 ) . In vivo ( 15 ) well clinical study ( 16 ) demonstrate superiority continuous bolus infusion 5FU . Over last several decade , concurrent 5FU radiation use successfully variety malignancy . Several important lesson learn clinical trial ( 16 ) . Simultaneous delivery large ( IV bolus ) dose 5 fluorouracil irradiation associate improved survival compare treatment radiation alone , price increase normal tissue toxicity . These side effect ameliorate use protract venous infusion . This efficacious approach , wide therapeutic index , permit concurrent treatment micrometastatic disease radiation sensitization . Combined modality therapy , include irradiation concurrently administer 5FU base chemotherapy , become mainstay therapy anal rectal cancer . Protracted venous infusion chemoradiation also use preoperative management rectal cancer nonoperative management anal cancer . The Gastrointestinal Tumor Study Group ( GITSG ) demonstrate significant survival advantage patient receive adjuvant combine radiation bolus 5FU follow curative resection pancreatic cancer ( 17,18 ) . Similar advantage demonstrate unresectable pancreatic cancer . Significant advantage also show concurrent chemotherapy regiment contain 5FU esophageal cancer ( 19 ) , squamous cell carcinoma Head Neck ( 20,21 ) , carcinoma cervix ( 22 ) . There limited experience use capecitabine radiation . Based relative selectivity increase tumor cell 5FU level , expect capecitabine provide superior radiosensitization equivalent reduce systemic toxicity level . Interestingly , recently report radiation induces thymidine phosphorylase enhances efficacy capecitabine human cancer xenograft ( 23 ) . This may enhance synergistic effect , consequently therapeutic ratio . In RTOG study substantial number patient gastrointestinal malignancy treat concurrent radiotherapy capecitabine dose 1600 mg/m2/day ( 5 day week ) little toxicity ( 24 ) .In phase II study chemoradiation rectal cancer 1650mg/m2/d capecitabine 14 day safe well-tolerated treatment ( 25 ) . In study investigate feasibility concurrent Capecitabine external beam radiotherapy , well collect preliminary data regard efficacy regimen . OBJECTIVES Hypothesis : Given hypothesis regimens employ great intensity radiation yield high rate pain relief , radiosensitization use tumor target drug like Xeloda improve rate complete pain relief compare radiosensitization 5FU alone . Primary Objective : To determine frequency duration pain relief narcotic relief propose regimen . Secondary Objective : To determine toxicity concurrent Capecitabine radiotherapy breast cancer patient bone metastasis . Eligibility Criteria Patients metastatic breast allow study regardless prior exposure chemotherapy . Today , evidence suggest crossresistance radiotherapy prior chemotherapy , response radiotherapy related way number line chemotherapy use particular patient . Good palliative response often achieve heavily pretreated patient . 1 . The patient must 18 year age old . 2 . The patient must histologically prove breast adenocarcinoma . 3 . Radiographic evidence bone metastasis require .Acceptable study include plain radiograph , radionuclide bone scan , compute tomography scan magnetic resonance imaging . 4 .The patient must pain appear relate radiographically document metastasis . 5 . Patients receive systemic therapy Capecitabine metastatic disease ( accord health basket ) . 6 . Patients must estimate life expectancy 3 month great . 7 . Patients eligible treatment multiple metastasis include two treatment site . 8 . Signed study specific inform consent . 9 Karnofsky Performance Status &gt; 40 . 10 . Calculated Creatinine Clearance &gt; 50 ml/min 11.ALT AST great 3 5 time institutional normal ; bilirubin serum creatinine great 1.5 time normal ; ANC great 1500 , platelet least 100,00 . Exclusion Criteria 1 . Prior radiation therapy prior palliative surgery painful site . 2 . Impending fracture treatment site plan surgical fixation bone . 3 . Patients clinical radiographic evidence spinal cord cauda equina compression . 4 . Patients receive systemic radionuclides ( strontium , samarium , etc . ) within 60 day prior registration . PRETREATMENT EVALUATION 1 . Histologic diagnosis primary site . 2 . Radiographic assessment , must include plain x-ray index lesion ( ) bone scane . 3 . Pain assessment score ( BPI ) . 4 . Laboratory studis within 2 week registration ( CBC , serum ALT , AST , total bilirubin creatinine ) . RADIATION THERAPY 1 . Treatment must give use 6-15MV photon 6-18 MeV electron . 2 . All field must treat day . Treatment volume include radiographic abnormality least 2 cm margin . Treatment entire bone require . 3 . Anterior posterior parallel oppose field use lumbar spine , sacrum , extremity site . Equal weighting recommend , although unequal weighting may use lumbar sacral spine ratio dose 1:2 AP : PA . Dose prescribe mid depth central axis , center target volume unequal weighting use . Alternatively , lumbar spine may treat single PA field , dose prescribe mid vertebral body define lateral simulator film . 4 . Single posterior field use thoracic spine scapula .The treatment depth set middle vertebral body , determine lateral simulation film . 5 . The cervical spine may treat either parallel opposed lateral field single posterior field . When lateral field use , isocenter mid thickness , dose prescribe mid vertebral body . 6 . Pubic . bone lesion treat single anterior field depth determine lateral radiograph CT scan . 7 . Clavicular lesion treat single anterior field depth 3 cm . The dose prescribed 3 cm depth . An alternative depth may use determine CT scan radiograph . 8 . Rib metastasis may treat electron photon . When electron use , appropriate energy choose entire lesion cover 90 % ( high ) isodose curve . The dose prescribed 100 % isodose line . When photon use , parallel oppose field may use , depth prescribe mid thickness . Tangential field strongly encourage avoid treatment underlying structure . A single field may use cover lesion , depth set estimate depth rib lesion , dose prescribe level . 9 . When one osseous site include treatment field , treat radiation oncologist may use different field arrangement herlhis discretion , goal provide relatively uniform coverage target sit minimum inclusion uninvolved tissue . Radiation Dose All patient receive radiotherapy dose 30 Gy 10fractions ( 3 Gy per fraction ) two week . CHEMOTHERAPY Chemotherapy capecitabine tablet give concurrently radiotherapy dose 1400 mg/m2 orally , two daily divide dos . Total daily dose round near 500 mg divide morning evening Doses , per follow table : Number 500 mg tablet take Surface Area Total Daily Dose morning evening ( m2 ) ( mg ) * &lt; = 1.08 1000 1 1 1.09 1.4 1500 2 1 1.41 1.71 2000 2 2 1.72 2.02 2500 3 2 *Total Daily Dose round near 500 mg divide morning evening dos . Dose Limiting Toxicity ) &gt; grade 3 non hematologic toxicity , except diarrhea , nausea , vomit , fatigue , anorexia , alopecia , fever and/or local reaction . ii ) grade 4 diarrhea last &gt; 3 day controllable loperamide medication . Or grade 4 diarrhea require IV hydration . iii ) grade 4 neutropenia last &gt; 3 day iv ) grade 4 thrombocytopenia v ) grade 2 hand foot syndrome . Dose adjustment per follow table : Toxicity NCI Grades During Course Therapy Grade 1 Maintain dose Grade 2 1st appearance ( non HFS ) Interrupt resolve grade 0 1 1st appearance HFS Interrupt resolve grade 0 1 , continue 75 % original dose . 2nd appearance Interrupt resolve grade 0 1 , continue 75 % original dose . 3rd appearance Interrupt resolve grade 0 1 , continue 50 % original dose . 4th appearance Discontinue treatment permanently Grade 3 1. st appearance Interrupt resolve grade 0 1 , continue 75 % original dose prophylaxis possible . 2. nd appearance Interrupt resolve grade 0 1 , continue 50 % original dose . 3. rd appearance Discontinue treatment permanently Grade 4 1st appearance Discontinue permanently If physician deems patient 's best interest continue , interrupt resolve grade 0 1 , continue 50 % original dose . Dosage modification recommend grade 1 event . Therapy capecitabine interrupt upon occurrence grade 2 3 adverse experience . Once adverse event resolve decreased intensity grade 1 , therapy may restart full dose adjust accord table . If grade 4 experience occurs , therapy discontinue interrupt resolve decreased grade 1 , therapy restart 50 % original dose . Doses capecitabine omit toxicity replace restore ; instead patient resume plan treatment cycle . Once dose reduce increase later time . Toxicity CAPECITABINE induce diarrhea , sometimes severe . Patients severe diarrhea carefully monitor give fluid electrolyte replacement become dehydrate . National Cancer Institute Canada ( NCIC grade 2 diarrhea define increase 4 6 stools/day nocturnal stool , grade 3 diarrhea increase 7 9 stools/day incontinence malabsorption , grade 4 diarrhea increase &gt; 10 stools/day grossly bloody diarrhea need parenteral support . If grade 2 , 3 4 diarrhea occurs , administration capecitabine immediately interrupt diarrhea resolve decrease intensity grade 1 . Following grade 3 4 diarrhea , subsequent dos capecitabine decrease . Standard antidiarrheal treatment ( eg , loperamide ) recommend . Necrotizing enterocolitis ( typhlitis ) also report . Hand foot syndrome ( palmar plantar erythrodysesthesia chemotherapy induce acral erythema ) characterize follow : numbness , dysesthesia/paresthesia , tingle , painless painful swelling , erythema , desquamation , blister severe pain . Grade 2 hand foot syndrome define painful erythema swell hand and/or foot and/or discomfort affect patient 's activity daily live . Grade 3 hand and¬foot syndrome define moist desquamation , ulceration , blister severe pain hand and/or foot and/or severe discomfort cause patient unable work perform activity daily live . If grade 2 3 hand foot syndrome occur , administration capecitabine interrupt event resolve decrease intensity grade 1 . Following occurrence grade 2 handand foot syndrome , subsequent dos capecitabine decrease . There cardiotoxicity associate fluorinated pyrimidine therapy , include myocardial infarction , angina , dysrhythmias , cardiogenic shock , sudden death electrocardiograph change . These adverse event may common patient prior history coronary artery disease . Patients mild moderate hepatic dysfunction due liver metastasis carefully monitor capecitabine administer . The effect severe hepatic dysfunction disposition capecitabine know . If drug relate grade 2 4 elevation bilirubin occur , administration capecitabine immediately interrupt hyperbilirubinernia resolve decrease intensity grade 1 . NCIC grade 2 hyperbilirubinernia define 1.5 x normal , grade 3 hyperbilirubinemia 1.5 3 x normal grade 4 hyperbilirubinemia &gt; 3 x normal . Increases adverse event note patient reduced renal function . Therefore , patient exclude calculated creatinine clearance le 50 ml/min . Myelosuppression rare . Assessment Response Pain score narcotic score determine use guideline follow table : PAIN AND NARCOTIC CATEGORIES AND SCORES PAIN ANALGESIA Severity 0 No pain 0 None I Mild I Analgesics ( ASA , Bufferin , Tylenol , Anacin , etc . ) 2 Moderate 2 Mild Narcotic , ( &lt; 112 gr . codeine , Darvon , etc . ) 3 Severe 3 Moderate Narcotic ( &gt; 112 &lt; gr . codeine , Percoan , etc ) 4 Strong 4 Narcotic , ( &gt; 1 gr . codeine , demerol , morphine , etc ) Frequency 0 None 0 None I Occasional ( &lt; daily ) I p.r.n . ( &lt; daily ) 2 Intermittent ( least daily ) 2 q.d . ( I tab . cap./day ) 3 Frequent ( &gt; . I &lt; 3 daily ) 3 b.i.d . t.i.d . ( &gt; I &lt; 4 tab . cap./day ) 4 Constant ( time ) 4 &gt; t.i.d . ( &gt; 4 tab . cap./day ) Pain Score = Pain Severity Grade x Pain Frequency Grade Narcotic Score = Analgesia Severity Grade x Analgesic Frequency Grade Response evaluate questionnaire follow visit 2 , 4 8 week completion radiotherapy phone call interview ( necessary completeness ) poor compliance patient . The `` bad pain score '' use response endpoint . The time maximal pain relief time first day irradiation time low pain score average pain . Response Definitions Complete response define average pain score 0 two consecutive analysis period . Narcotic consumption must increase . Partial response . A decrease least 2 point worst pain score two consecutive analysis period . Narcotic consumption must increase . No response ( follow ) : A pain score change within 8 week start radiation therapy . A 2 point increase bad pain score sustain high level month follow first day radiation therapy . A pain score drop least 2 point subsequent sustain rise ( 2 successive questionnaire ) pain score least 2 point . Any patient progressive pain treat area plain radiographs area ass bone stability pathologic fracture . References . 1 . Hoskin PJ . Scientific clinical aspect radiotherapy relief bone pain . Cancer Surv . 7:69 , 1988 . 2 . Tong D , Gillick L , Hendrickson FR . The palliation symptomatic osseous metastasis : result Radiation Therapy Oncology Group . Cancer 1982 ; 50 : 893 . 3 . Hoskin PJ , Price P , Easton D , et ] . A prospective randomize trial 4 Gy 8 Gy single dos treatment metastatic bone pain . Radiotherapy Oncology 23:74 78 , 1992 . 4 . Price P , Hoskin PJ , Easton D , et al . Prospective randomize trial single multifraction radiotherapy schedule treatment painful bony metastasis . Radiotherapy Oncology 6 : 247 255 , 1986 . Okawa T , Kita M , Goto M , et al . Randomized prospective clinical study small , large twice day fraction radiotherapy painful bone metastasis . Radiotherapy Oncology 13 : 99 104 , 1988 . 6 . Madsen EL , Painful bone metastasis : Efficacy radiotherapy assess patient : A randomized trial compare 4 Gy x 6 versus 10 Gy x 2 . Int . J. Radiat . Oncol . Biol . Phys . 9:1775¬ 1779 , 1983 . 7 . Blitzer PH . Reanalysis RTOG study palliation symptomatic osseous metastasis . Cancer 1985 ; 55 : 1468 1472 . 8 . Orton CG , Ellis F , A simplification use NSD concept practical radiotherapy . Br . J. Radiol . 1973 ; 46:529 537 . 9 . Daut R , Cleeland C , Flanery R : Development Wisconsin Brief Pain questionnaire ass pain cancer disease . Pain 17:197 210 , 1983 . 10 . 11 . 12 . 13 . 14 . Cella DF , Tulsky DS , Gray G , et al . : The Functional Assessment Cancer Therapy Scale : Development validation general measure . J Clin Oncol 11:570 579 , 1993 . Ben Josef E , Shamsa F , Youssef E , Porter AT . External beam radiotherapy painful osseous metastasis : pool data dose response analysis . Int J Radiat Oncol Biol Phys 45 ( 3 ) :715 719 , 1999 . Byfield JE , calabro Jones P , Klisak 1 , et al . Pharmacologic requirement obtain sensitization human tumor cell vitro combine r fluorouracil ftorafur x ray . Int J Radiat Oncol Biol Phys 1982 , 8:1923 33 . Nakajima V , Miyamoto Y , Tanabe M , et al . Enhancement mammalian cell kill 5fluorouracil combination x ray . Cancer Res 39:3763 3767 , 1979 . Lawrence TS , Davis MA , Maybaum I Dependence 5 fluorouracil mediate radiosensitization DNA direct effect . Int J Radiat Oncol Biol Phys 1994 , 29 ( 3 ) :519 23 . 15 . Weinberg MJ , Rauth AM . 5 fluorouracil infusion fractionate dos radiation : Studies murine sqamous cell carcinoma . Int J Radiat Oncol Biol Phys 13 : 1691 1699 , 1987 . Rich TA . Infusional chemoradiation rectal anal cancer . Oncology ( Huntingt ) 1999 , 13 ( 10 Suppl 5 ) :131 4 . 17 . Gastrointestinal Tumor Study Group . Further evidence effective adjuvant combine radiation chemotherapy follow curative resection pancreatic cancer . Cancer 1987 , 59 ( 12 ) :2006¬ 10 . 18 . Kalser MH , Ellenberg SS . Pancreatic cancer . Adjuvant combine radiation chemotherapy follow curative resection . Arch Surg 1985 , 120 ( 8 ) :899 903 . 19. al Sarraf M , Martz K , Herskovic A , Leichman L , Brindle JS , Vaitkevicius VK , Cooper J , Byhardt R , Davis L , Emami B . Progress report combine chemoradiotherapy versus radiotherapy alone patient esophageal cancer : intergroup study . J Clin Oncol 1997 , 15 ( l ) :277 84 . 20 . Wendt TG , Grabenbauer GG , Rodel CM , Thiel HJ , Aydin H , Rohloff R , Wustrow TP , Iro H , Popella C , Schalhorn A . Simultaneous radiochemotherapy versus radiotherapy alone advanced head neck cancer : randomize multicenter study . J Clin Oncol 1998 , 16 ( 4 ) :1318 24 . 21 . Al Sarraf M , LeBlanc M , Giri PG , Fu KK , Cooper J , Vuong T , Forastiere AA , Adams G , Sakr WA , Schuller DE , Ensley JF . Chemoradiotherapy versus radiotherapy patient advanced nasopharyngeal cancer : phase III randomize Intergroup study 0099 . J Clin Oncol 1998 , 16 ( 4 ) :1310 7 . 22 . Morris M , Eifel PJ , Lu J , Grigsby PW , Levenback C , Stevens RE , Rotman M , Gershenson DM , Mutch DG . Pelvic radiation concurrent chemotherapy compare pelvic para aortic radiation high risk cervical cancer . N Engl J Med 1999 , 340 ( 15 ) :1137 43 . 23 . Sawada N , Ishikawa T , Sekiguchi F , Tanaka Y , Ishitsuka H. X ray irradiation induces thymidine phosphorylase enhances efficacy capecitabine human cancer xenograft . Clin Cancer Res 1999 , 5 ( 10 ) :2948 53 . 24 . U.N.Vaishampayan , E. Ben-Josef , P.A . Philip , V.K . Vaitkevicius , K.J . Levin A.F . Shields . A single- institution experience concurrent capecitabine radiation therapy gastrointestinal malignancy . Int J Radiat Oncol Biol Phys ,2002 , 53,675-679 . 25 . Jun-Sang Kim , Jae-Sung Kim , Moon-June Cho Wan-Hee Yoon .Preoperative chemoradiation use oral capecitabine locally advanced rectal cancer . Int J Radiat Oncol Biol Phys ,2002,54,403-408 .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>1 . The patient must 18 year age old 2 . The patient must histologically prove breast adenocarcinoma 3 . Radiographic evidence bone metastasis require .Acceptable study include plain radiograph , radionuclide bone scan , compute tomography scan magnetic resonance image 4 . The patient must pain appear relate radiographically document metastasis 5 . Patients receive systemic therapy Capecitabine metastatic disease ( accord health basket ) 6 . Patients must estimate life expectancy 3 month great 7 . Patients eligible treatment multiple metastasis include two treatment sit 8 . Signed study specific inform consent 9 . Karnofsky Performance Status &gt; 40 10 . Calculated Creatinine Clearance &gt; 50 ml/min 11 . ALT AST great 3 5 time institutional normal ; bilirubin serum creatinine great 1.5 time normal ; ANC great 1500 , platelet least 100,00 1 . Prior radiation therapy prior palliative surgery painful site 2 . Impending fracture treatment site plan surgical fixation bone 3 . Patients clinical radiographic evidence spinal cord cauda equina compression 4 . Patients receive systemic radionuclides ( strontium , samarium , etc . ) within 60 day prior registration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>